Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population

Journal of Hypertension

Volumn 29, Issue 8, 2011, Pages 1553-1559

  Sim, John J ^a   Yan, Eric H ^a   Liu, In Lu A ^b   Rasgon, Scott A ^a   Kalantar Zadeh, Kamyar ^c   Calhoun, David A ^d   Derose, Stephen F ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

hyperaldosterone; secondary hypertension; sleep apnea

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANFACINE; LOOP DIURETIC AGENT; METHYLDOPA; RENIN; RENIN INHIBITOR; RESERPINE; THIAZIDE DIURETIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HISPANIC; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PLASMA RENIN ACTIVITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SLEEP APNEA SYNDROME; UNITED STATES;

EID: 79960615523     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283492219     Document Type: Article

References (50)

1. Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB, Dempsey J. Sleep apnea and hypertension. A population-based study. Ann Intern Med 1994; 120:382-388. (Pubitemid 24066635)
2. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283:1829-1836. (Pubitemid 30207619)
3. Sim JJ, Rasgon SA, Derose SF. Sleep apnea and hypertension: prevalence in chronic kidney disease. J Clin Hypertens (Greenwich) 2007; 9:837-841.
4. Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11:165-172.
5. Kato M, Roberts-Thomson P, Phillips BG, Haynes WG, Winnicki M, Accurso V, et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102:2607-2610.
6. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999; 34:309-314. (Pubitemid 29409233)
7. Yamauchi M, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Suzuki T, et al. Oxidative stress in obstructive sleep apnea. Chest 2005; 127:1674-1679. (Pubitemid 46218794)
8. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43:518-524. (Pubitemid 38282420)
9. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14 (6 Pt 1):491-503. (Pubitemid 32506721)
10. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132:440-446. (Pubitemid 47282374)
11. Shiota S, Ryan CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007; 62:868-872. (Pubitemid 47598351)
12. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125:112-117. (Pubitemid 38114572)
13. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271-2277. (Pubitemid 33135251)
14. Laragh JH. The role of aldosterone in man. Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension. JAMA 1960; 174:293-295.
15. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. Renin angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
16. Young WF Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 144:2208-2213. (Pubitemid 36629868)
17. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248. (Pubitemid 40523144)
18. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90:5070-5076. (Pubitemid 41262256)
19. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
20. Bhandari SK, Pashayan S, Liu IL, Rasgon SA, Kujubu DA, Tom TY, et al. 25-hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich) 2011; 13:170-177.
21. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153:2125-2129. (Pubitemid 23286466)
22. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89:4221-4226. (Pubitemid 39244414)
23. Sim JJ, Rasgon SA, Kujubu DA, Kumar VA, Liu IL, Shi JM, et al. Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 2009; 135:710-716.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
25. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378-1384. (Pubitemid 30262394)
26. Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, et al. Populationbased study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997; 157:1746-1752. (Pubitemid 27327411)
27. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131:453-459.
28. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921-1926. (Pubitemid 351778191)
29. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896. (Pubitemid 35434912)
30. Stradling J, Davies RJ. Sleep apnea and hypertension: what a mess!. Sleep 1997; 20:789-793. (Pubitemid 27506209)
31. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010; 24:532-537.
32. Saarelainen S, Hasan J, Siitonen S, Seppala E. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res 1996; 5:181-185. (Pubitemid 26380247)
33. Ancoli-Israel S, Kripke DF, Klauber MR, Mason WJ, Fell R, Kaplan O. Sleepdisordered breathing in community-dwelling elderly. Sleep 1991; 14:486-495.
34. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med 1998; 157:144-148. (Pubitemid 28071275)
35. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165:1217-1239. (Pubitemid 34461732)
36. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353:2034-2041. (Pubitemid 41609096)
37. Villaneuva AT, Buchanan PR, Yee BJ, Grunstein RR. Ethnicity and obstructive sleep apnoea. Sleep Med Rev 2005; 9:419-436. (Pubitemid 41630721)
38. Redline S, Tishler PV, Hans MG, Tosteson TD, Strohl KP, Spry K. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. Am J Respir Crit Care Med 1997; 155:186-192. (Pubitemid 27053162)
39. Ancoli-Israel S, Klauber MR, Stepnowsky C, Estline E, Chinn A, Fell R. Sleep-disordered breathing in African-American elderly. Am J Respir Crit Care Med 1995; 152 (6 Pt 1):1946-1949.
40. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 2005; 45:766-772.
41. Kotchen TA, Kotchen JM, Grim CE, Krishnaswami S, Kidambi S. Aldosterone and alterations of hypertension-related vascular function in African Americans. Am J Hypertens 2009; 22:319-324.
42. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431. (Pubitemid 35340538)
43. Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 1975; 40:125-134.
44. Naito Y, Tsujino T, Matsumoto M, Okuda S, Sakoda T, Ohyanagi M, et al. The mechanism of distinct diurnal variations of renin-angiotensin system in aorta and heart of spontaneously hypertensive rats. Clin Exp Hypertens 2009; 31:625-638.
45. Young WF Jr, Hogan MJ, Klee GG, Grant CS, van Heerden JA. Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc 1990; 65:96-110. (Pubitemid 20061930)
46. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877-885.
47. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902. (Pubitemid 35434913)
48. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699-705. (Pubitemid 32268029)
49. Peralta CA, Shlipak MG, Fan D, Ordonez J, Lash JP, Chertow GM, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 2006; 17:2892-2899. (Pubitemid 44484680)
50. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.